Compare AbCellera Biologics Inc (ABCL) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares China Large-Cap ETF — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while iShares China Large-Cap ETF trades at $33.51. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | FXI | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $41.75 |
52-Week Low | $2.78 | $31.59 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
The iShares China Large-Cap ETF (FXI) trades at $32.51, up 1.88% on the day, while technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. Recent news highlights China's AI and chip sector driving factory rebounds and IPO activity, though broader sentiment on Chinese equities remains mixed, with some analysts labeling them as potential value traps. The ETF shows neutral oscillator readings with key support at $32 and resistance at $33.
The outlook for FXI is clouded by structural macroeconomic headwinds in China, including deflationary pressures and geopolitical tensions with the U.S., which offset potential opportunities from the country's massive AI infrastructure investment plans. While the sector benefits from technology self-reliance initiatives, persistent risks to corporate profitability and valuation compression suggest a cautious approach for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
